NuP-3
NuP-3 is an orally active dual inhibitor of MAPK13 (IC50 < 250 nM), MAPK14 (IC50 = 7 nM), MAPK12 and MAPK11. NuP-3 blocks airway inflammation and mucus production. NuP-3 is used for the research of respiratory system diseases.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 2392969-05-8
- 分子式: C24H24ClFN4O3
- 分子量:470.92
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
NuP-3 (Compound 396) at 0.1 μM selectively inhibits MAPK13, MAPK14, MAPK11, and MAPK12; in a cell-free kinome screening, only 4% of the 400 tested kinases show an inhibition rate > 90%[1].
NuP-3 (21 days) potently inhibits MUC5AC production in primary human tracheobronchial epithelial cells stimulated by IL-13, with an IC50 of 0.005 nM within 21 days and a cell therapeutic index of 200000, indicating high safety[1].
NuP-3 (21 days) inhibits MUC5AC production in primary porcine tracheobronchial epithelial cells stimulated by IL-13, with an IC50 of 0.420 nM within 21 days and a cellular therapeutic index of 2381, indicating low toxicity[1].
NuP-3 (100 nM; 21 days) reduces IL-13-induced MUC5AC production in primary human tracheobronchial epithelial cells with MAPK gene knockout via CRISPR/Cas9[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
NuP-3 (2 mg/kg; p.o.; twice daily; 24 days) blocks virus-induced airway mucus production in Yucatan mini-pigs[1].
NuP-3 (2 mg/kg; i.p.; twice daily) blocks virus-induced airway mucus production, epithelial reprogramming, and type 2 immune response in mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Yucatan mini-pigs (male and female, 7-8 weeks of age, 21-25 kg, IL-13-challenged model)[1]
-
Dosage:0.2 mg/kg; 2 mg/kg; 20 mg/kg
-
Administration:p.o.; twice daily; 6 days
-
Result:Significantly decreased BAL fluid levels of MUC5AC and CLCA1, and significantly reduced eosinophil and neutrophil influx into the airspace at 2 mg/kg compared to vehicle control.
Showed decreased anti-mucus and anti-inflammatory effects at 0.2 mg/kg and preserved effects at 20 mg/kg compared to vehicle control.
Observed no adverse effects (behavior, appetite, body weight, vital signs, gastrointestinal/urinary function, complete blood count) at any dose.
-
Animal Model:Yucatan mini-pigs (male and female, 7-8 weeks of age, 21-25 kg, Sendai virus-infected model)[1]
-
Dosage:2 mg/kg
-
Administration:p.o.; twice daily; 24 days
-
Result:Significantly attenuated SeV-induced increases in BAL fluid levels of MUC5AC and CLCA1 compared to vehicle control.
Did not alter viral titer or cause detectable adverse effects.
-
Animal Model:Mice[1]
-
Dosage:2 mg/kg
-
Administration:i.p.; twice daily; 23 days (pre-infection); twice daily; 11 days (delayed post-infection)
-
Result:Fully blocked SeV-induced increases in lung tissue Muc5ac, Clca1, Aqp3, Krt5, Trp63, Il33, Il13, and Arg1 mRNA levels compared to vehicle control when administered starting 2 days before infection.
Significantly attenuated the aforementioned mRNA levels compared to vehicle control when treatment was delayed until 10 days post-infection.
Did not affect mouse behavior, body weight, or clinical signs of infection.
化学情報
-
CAS 番号 2392969-05-8
-
分子量 470.92
-
分子式 C24H24ClFN4O3
-
SMILES
O=C(NC1=CC(C(C)(C)C)=CC=C1Cl)NC2=CC=C(C=C2F)OC3=CC(NC(C)=O)=NC=C3
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
NuP-3 関連分類
HY-186241 関連分類
Powered by Bioz